Law Offices of Todd M. Garber Announces Investigation of AVEO Pharmaceuticals, Inc.

LOS ANGELES--(BUSINESS WIRE)--

The Law Offices of Todd M. Garber announces that it is investigating potential claims against AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”) AVEO concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by the Company between January 3, 2012 and May 1, 2013 regarding AVEO's business and financial prospects.

AVEO engages in discovering, developing and commercializing targeted cancer therapies. The investigation is related to allegations that the Company issued materially false and misleading statements regarding the Phase III trial design and results for the Company's drug Tivopath, or tivozanib, for the treatment of advanced kidney cancer. Specifically, the investigation concerns whether the Company misrepresented or failed to disclose that: (1) the FDA had recommended that the Company conduct an additional Phase III trial due to adverse trends in the Company's first Phase III trial; (2) there was a 25% higher rate of death associated with tivozanib therapy compared to the control drug, sorafenib; and (3) almost 90% of patients studied in the single Phase III trial were enrolled from sites in Central and Eastern Europe with inconsistent treatment patterns from those in the United States.

If you purchased AVEO shares between January 3, 2012 and May 1, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or purchased AVEO stock prior to January 3, 2012, please contact Todd M. Garber, Esquire, of the Law Offices of Todd M. Garber, by telephone at 213-700-7262 or by email to info@toddgarberlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.